XML 44 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholders’ Equity and Stock-Based Compensation (Tables)
12 Months Ended
Dec. 30, 2023
Equity [Abstract]  
Schedule of Non-vested Restricted Stock Activity

 

   Shares   Weighted Average Grant Fair Value 
Balance at December 25, 2021   2,077,592   $2.90 
Granted   1,013,600    1.33 
Forfeited   (444,350)   2.45 
Vested   (680,941)   2.82 
Balance at December 31, 2022   1,965,901    2.22 
Granted   3,423,531    1.58 
Forfeited   (1,089,773)   2.52 
Vested   (2,367,892)   1.62 
Balance at December 30, 2023   1,931,767   $1.65 
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions

 

Expected volatility   94.2%
Interest rate   0.2%
Expected life (years)   0.7 
Dividend yield   %
Schedule of Stock-based Compensation Expense

The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the fiscal years 2023, 2022 and 2021 (no tax benefits were recognized):

 

   2023   2022   2021 
Cost of product revenues  $1,210,453   $94,634   $211,362 
Research and development   861,324    435,842    576,193 
Selling, general and administrative   1,803,496    737,229    3,629,867 
Total  $3,875,273   $1,267,705   $4,417,422